Phase 4
N=100
Glucagon Use in Colonoscopies
Colon Cancer
Bottom Line
View on ClinicalTrials.gov: NCT02078726 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Apr 2021
Primary outcome: Primary: Adenoma Detection Rate (ADR) During Colonoscopy Procedure — 43.75; 33.33 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Glucagon (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adenoma Detection Rate (ADR) During Colonoscopy Procedure |
43.75; 33.33 | — |
Summary
The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.
Eligibility Criteria
Inclusion Criteria
- Any subject who has already been already cleared for and scheduled to undergo colonoscopy at SFGH endoscopy center.
Exclusion Criteria
- Refusal to give informed consent.
- Age 70.
- Prior intra-abdominal surgery
- Diabetes
- Pheochromocytoma
- Insulinoma
- Liver disease (Child-Pugh Score >6)
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT02078726). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.